These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15152956)

  • 41. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet.
    Weisberg E; Ayton R; Darling G; Farrell E; Murkies A; O'Neill S; Kirkegard Y; Fraser IS
    Climacteric; 2005 Mar; 8(1):83-92. PubMed ID: 15804736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause.
    Repse-Fokter A; Takac I; Fokter SK
    Gynecol Endocrinol; 2008 Jul; 24(7):399-404. PubMed ID: 18645712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parenteral versus oral treatment of postmenopausal women with estrogen.
    Stanczyk FZ
    Menopause; 2007; 14(6):968-70. PubMed ID: 17898669
    [No Abstract]   [Full Text] [Related]  

  • 44. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Bérubé R; Bélanger P; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):897-906. PubMed ID: 19436226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
    Freedman M; Kaunitz AM; Reape KZ; Hait H; Shu H
    Menopause; 2009; 16(4):735-41. PubMed ID: 19252451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Vaginal and intrauterine drug absorption. Bioadhesive and delayed-action preparations].
    Dittgen M
    Med Monatsschr Pharm; 1998 Jul; 21(7):197-201. PubMed ID: 9691627
    [No Abstract]   [Full Text] [Related]  

  • 47. Conjugated estrogens (Premarin) vaginal cream.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):14-5. PubMed ID: 19229162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relief of vaginal discomfort - hormones or water?
    Thompson E
    Climacteric; 2011 Jun; 14(3):398-9; author reply 399. PubMed ID: 21563997
    [No Abstract]   [Full Text] [Related]  

  • 49. NITROFURAZONE-ESTROGEN VAGINAL SUPPOSITORIES IN THE TREATMENT OF ATROPHIC VAGINITIS.
    FRIEDMAN JA; OLSEN N
    J Am Geriatr Soc; 1965 Sep; 13():828-31. PubMed ID: 14341031
    [No Abstract]   [Full Text] [Related]  

  • 50. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of estradiol valerate and levonorgestrel on vaginal health.
    Manonai J; Chittacharoen A; Theppisai U
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):190-3. PubMed ID: 15262354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytohormonal and morphological alterations in cervicovaginal smears of postmenopausal women on hormone replacement therapy.
    Gupta S; Kumar N; Singhal N; Manektala U; Jain S; Sodhani P
    Diagn Cytopathol; 2006 Oct; 34(10):676-81. PubMed ID: 16955474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atrophic vaginitis: signs, symptoms, and better outcomes.
    Reimer A; Johnson L
    Nurse Pract; 2011 Jan; 36(1):22-8; quiz 29. PubMed ID: 21150811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mayo Clinic office visit. Vaginal dryness. An interview with Rosalina Abboud,M.D.
    Abboud R
    Mayo Clin Womens Healthsource; 2009 Jun; 13(6):6. PubMed ID: 19415047
    [No Abstract]   [Full Text] [Related]  

  • 56. Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: hormone precursor replacement therapy (HPRT).
    Buster JE
    Menopause; 2009; 16(5):858-9. PubMed ID: 19574935
    [No Abstract]   [Full Text] [Related]  

  • 57. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non-controlled clinical trial.
    Costantino D; Guaraldi C
    Eur Rev Med Pharmacol Sci; 2008; 12(6):411-6. PubMed ID: 19146203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective topical treatments for atrophic vaginitis.
    Doyle H
    JAAPA; 2006 Oct; 19(10):33-8. PubMed ID: 17066678
    [No Abstract]   [Full Text] [Related]  

  • 59. Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis.
    Karaosmanoglu O; Cogendez E; Sozen H; Asoglu MR; Akdemir Y; Eren S
    Int J Gynaecol Obstet; 2011 May; 113(2):156-7. PubMed ID: 21420087
    [No Abstract]   [Full Text] [Related]  

  • 60. Estrogen treatment for incontinence in frail older women.
    Ouslander JG; Cooper E; Godley D
    J Am Geriatr Soc; 1999 Nov; 47(11):1383-4. PubMed ID: 10573454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.